Fluticasone furoate, a novel corticosteroid, maintains glucocorticoid receptor nuclear localisation for 24 hours after washout in monocytes Source: Annual Congress 2011 - Translational models of disease Year: 2011
Activated protein phosphatase PP2A by formoterol enhances nuclear translocation of glucocorticoid receptor induced by budesonide Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Higher cellular retention and activity after pulse exposure by budesonide (BUD) than fluticasone propionate (FP) and mometasone furoate (MF) Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001
Formoterol enhances glucocorticoid receptor nuclear translocation in steroid-insensitive severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 250s Year: 2004
Fluticasone furoate restores leptin/leptin receptor pathway in nasal epithelial cells Source: Annual Congress 2011 - Lung cell biology Year: 2011
Inhibitory activity of fluticasone propionate (FP) and salmeterol (SAL) on TGF-β–induced expression of α-smooth muscle actin (α-SMA) by human primary airway fibroblasts (Fbs) Source: Annual Congress 2003 - Cell signalling and cytokines in asthma Year: 2003
Mometasone furoate is a less specific glucocorticoid than fluticasone propionate Source: Eur Respir J 2002; 20: 1386-1392 Year: 2002
Fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), demonstrates once-daily (OD) efficacy in asthma when dosed in the evening Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Inhibitory activity of fluticasone propionate (FP), on the constitutive or cytokine-induced bronchial epithelial cell (HBECs) functions in vitro Source: Eur Respir J 2003; 22: Suppl. 45, 76s Year: 2003
The combination salmeterol (S) + fluticasone propionate (F) in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long-acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbations Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Modulation of TNFα-induced ICAM-1 expression in a human bronchial epithelial cell line (Beas-2B) by roflumilast N-oxide (RNO), salmeterol (Sal) and budesonide (Bud) Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II Year: 2007
Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
Improved patient compliance with salmeterol/fluticasone propionate combination (SFC) compared with regular long-acting β2 agonist (LAB) and inhaled steroid (IS) therapy Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Synergistic inhibition of salmeterol with fluticasone propionate or rolipram on stimulated eosinophil binding of β2 -integrin to ICAM-1 and cytosolic gIV-phospholipase A2 activation Source: Eur Respir J 2003; 22: Suppl. 45, 455s Year: 2003
The effect of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Lack of effect of promoter, coding and 3‘ polymorphisms of the β2 -adrenergic receptor (ADRB2 ) on the clinical response to salmeterol alone or with fluticasone propionate in subjects with asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
The pharmacokinetics (PK) and pharmacodynamics (PD) of the fluticasone furoate (FF) and vilanterol (VI) combination in subjects with hepatic impairment Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects. Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019